Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

NYU Langone Health36 enrolled

Overview

This is a Phase II, open label, non-randomized study in subjects with histologically confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who have not received prior chemotherapy for metastatic disease.

The current treatment options for metastatic colon cancer are in need of further improvement. The three-drug combination of oxaliplatin with 5-FU/LV (fluorouracil/leucovorin) in the second-line treatment of metastatic colorectal cancer have shown a significant increase in response rate compared to 5-FU/LV alone. Oxaliplatin has recently been FDA-approved for this indication and is now a standard first-line agent in combination with a fluoropyrimidine. Cetuximab, a chimeric monoclonal antibody against the growth factor receptor, has shown activity with and without irinotecan in subjects with colorectal cancer refractory to irinotecan alone. Cetuximab has also been shown to be safe and effective when administered with infusional 5-FU/folinic acid plus irinotecan. These results suggest that the addition of cetuximab to fluoropyrimidine/oxaliplatin-based regimen in the 1st line setting should be explored. The use of the oral fluoropyrimidine, capecitabine, to replace infusional 5FU has been widely used for improved convenience and possible safety. We have chosen a modified biweekly CapeOx (capecitabine plus oxaliplatin) regimen due to its improved tolerance and response rate with a fixed dose of capecitabine given its widespread practice and ease of use.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Cancer Neoplasm Metastasis

Interventions

CetuximabDRUG

500 mg/m2, IV every two weeks

OxaliplatinDRUG

85 mg/m2, IV, q 2 weeks

CapecitabineDRUG

2500 mg, po bid x 7 days every two weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must have signed an approved informed consent. * Histologically confirmed diagnosis of advanced adenocarcinoma of the colon or rectum, with KRAS wild type on mutational analysis. * No prior chemotherapy for metastatic disease (chemotherapy naive). Prior adjuvant therapy with 5FU/LV or IFL (irinotecan, fluorouracilis, and leucovorin (folinic acid)) permitted if completed at least six months prior to entering this study. * Measurable disease by RECIST criteria as defined in Section 3.3.1. * Subjects for whom tumor tissue is available for IHC ( Immunohistochemistry) testing for EGFR expression. * ECOG (Eastern Cooperative Oncology Group) Performance Status 0-1. * Recovery in full from any previous surgical procedure. * Expected survival greater than 12 weeks. * Subjects at least 18 years of age. * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study medication. * Adequate hematologic function defined by an absolute neutrophil count (ANC) \> 1,500/mm3, a platelet count \> 100,000/mm3 . * Adequate hepatic function defined by a total bilirubin level no greater than 2.0 times the upper limit of normal (ULN) and AST (Aspartate Aminotransferase) and ALT (alanine transaminase) levels noo greater than 2.5 times the ULN (AST and ALT levels no greater than 5 times the ULN in the presence of liver metastases). * Adequate renal function defined by a serum creatinine level no greater than 1.5 times the ULN. Exclusion Criteria: * WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study. * Women who are pregnant or breastfeeding. * Women with a positive pregnancy test on enrollment or prior to study drug administration. * Sexually active fertile men not using effective birth control if their partners are women of child-bearing potential. * Subjects with \> Grade 1 neuropathy. * Any active or uncontrolled infection. * History of myocardial infarction within the previous six months or current clinical evidence of congestive heart failure. * History of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 5 years. * Central nervous system metastases. * Pregnant or lactating women. Men and women of reproductive potential must agree to use an effective contraceptive method. * Medical or psychiatric disorders that would interfere with informed consent or make them a poor risk for participation in this trial. * Prior allergic reaction to chimerized or murine monoclonal antibody therapy or documented presence of human anti-mouse antibodies (HAMA). * Subjects receiving a prior investigational agent within 30 days. * Prior therapy with oxaliplatin, cetuximab, or prior therapy that targets the EGF ( epidermal growth factor) pathway. * Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study. * Mutation in the KRAS gene

Locations (2)

Bellevue Hospital

New York, New York, United States

New York University Langone Medical Center

New York, New York, United States

Outcomes

Primary Outcomes

Response Rate for the Combination Treatment

The tumor response rate (RR) will be defined as the total number of subjects whose best response is partial response (PR) or complete response (CR) during the first six months of treatment, divided by the number of subjects.

Time frame: 6 months since the start of treatment

Secondary Outcomes

Toxicity Rates

\# of subjects who experienced \>= grade 1 adverse event that is positively related to treatment.

Time frame: 1 year since the first treatment and every year after for up to 10 years

Time to Progression

Time to Treatment Failure (progression or death) will be defined as the time from the first day of treatment until the date Progressive Disease (PD) or death is first reported. Subjects who die without a reported prior progression will be considered to have progressed on the day of their death. Subjects who did not progress will be censored at the day of their last tumor assessment.

Time frame: 6 months since the start of treatment and every 3 months after treatment for up to 10 years

Survival

Survival will be defined as the number of days from the first day of therapy to the date of death. If the subject is lost to follow-up, survival will be censored on the last date the subject was known to be alive.

Time frame: 6 months since the start of treatment and every 3 months after treatment for up to 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.